                         SEQUENCE LISTING

<110>  Seattle Genetics, Inc.
 
<120>  METHODS OF PURIFYING MASKED ANTIBODIES

<130>  01218-0004-00PCT

<150>  US 62/857,367
<151>  2019-06-05

<160>  43    

<170>  PatentIn version 3.5

<210>  1
<211>  32
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VelA coiled-coil

<400>  1

Val Ala Gln Leu Glu Glu Lys Val Lys Thr Leu Arg Ala Glu Asn Tyr 
1               5                   10                  15      


Glu Leu Lys Ser Glu Val Gln Arg Leu Glu Glu Gln Val Ala Gln Leu 
            20                  25                  30          


<210>  2
<211>  32
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VelB coiled-coil

<400>  2

Val Asp Glu Leu Gln Ala Glu Val Asp Gln Leu Glu Asp Glu Asn Tyr 
1               5                   10                  15      


Ala Leu Lys Thr Lys Val Ala Gln Leu Arg Lys Lys Val Glu Lys Leu 
            20                  25                  30          


<210>  3
<211>  47
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VelA-IPV

<400>  3

Gly Ala Ser Thr Thr Val Ala Gln Leu Glu Glu Lys Val Lys Thr Leu 
1               5                   10                  15      


Arg Ala Glu Asn Tyr Glu Leu Lys Ser Glu Val Gln Arg Leu Glu Glu 
            20                  25                  30          


Gln Val Ala Gln Leu Gly Ser Ile Pro Val Ser Leu Arg Ser Gly 
        35                  40                  45          


<210>  4
<211>  47
<212>  PRT
<213>  Artificial sequence

<220>
<223>  VelB-IPV

<400>  4

Gly Ala Ser Thr Ser Val Asp Glu Leu Gln Ala Glu Val Asp Gln Leu 
1               5                   10                  15      


Glu Asp Glu Asn Tyr Ala Leu Lys Thr Lys Val Ala Gln Leu Arg Lys 
            20                  25                  30          


Lys Val Glu Lys Leu Gly Ser Ile Pro Val Ser Leu Arg Ser Gly 
        35                  40                  45          


<210>  5
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  5

Gly Ser Gly Gly Ser 
1               5   


<210>  6
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  6

Gly Gly Gly Ser 
1               


<210>  7
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  7

Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser 
1               5                   10          


<210>  8
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  8

Gly Gly Ala Ala 
1               


<210>  9
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  9

Gly Gly Gly Gly Ser 
1               5   


<210>  10
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  10

Leu Ala Ala Ala Ala 
1               5   


<210>  11
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  11

Gly Gly Ser Gly 
1               


<210>  12
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  12

Gly Gly Ser Gly Gly 
1               5   


<210>  13
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  13

Gly Ser Gly Ser Gly 
1               5   


<210>  14
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  14

Gly Ser Gly Gly Gly 
1               5   


<210>  15
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  15

Gly Gly Gly Ser Gly 
1               5   


<210>  16
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary linker

<400>  16

Gly Ser Ser Ser Gly 
1               5   


<210>  17
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary protease site


<220>
<221>  misc_feature
<222>  (4)..(6)
<223>  Xaa can be any naturally occurring amino acid

<400>  17

Pro Leu Gly Xaa Xaa Xaa 
1               5       


<210>  18
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary protease site

<400>  18

Pro Leu Gly Val Arg 
1               5   


<210>  19
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary protease site

<400>  19

Ile Pro Val Ser Leu Arg Ser Gly 
1               5               


<210>  20
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary protease site

<400>  20

Leu Ser Gly Arg Ser Asp Asn Tyr 
1               5               


<210>  21
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Exemplary protease site

<400>  21

Gly Pro Leu Gly Val Arg 
1               5       


<210>  22
<211>  118
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Heavy chain variable sequence of hB6H12.3 and hB6H12.3 
       (deamidation mutant)

<400>  22

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
            20                  25                  30          


Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val 
        35                  40                  45              


Ala Thr Ile Thr Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ser Leu Ala Gly Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr 
            100                 105                 110         


Leu Val Thr Val Ser Ser 
        115             


<210>  23
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Light chain variable sequence of hB6H12.3

<400>  23

Glu Ile Val Met Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Lys Phe Ala Ser Gln Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Gly His Gly Phe Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  24
<211>  108
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Light chain variable sequence of hB6H12.3 (deamidation mutant)

<400>  24

Glu Ile Val Met Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys 
1               5                   10                  15      


Glu Lys Val Thr Leu Thr Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr 
            20                  25                  30          


Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Lys Phe Ala Ser Gln Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala 
65                  70                  75                  80  


Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Ala His Gly Phe Pro Arg 
                85                  90                  95      


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 
            100                 105             


<210>  25
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR1 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  25

Gly Tyr Gly Met Ser 
1               5   


<210>  26
<211>  17
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR2 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  26

Thr Ile Thr Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  27
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  27

Ser Leu Ala Gly Asn Ala Met Asp Tyr 
1               5                   


<210>  28
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR1 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  28

Gly Phe Thr Phe Ser Gly Tyr Gly 
1               5               


<210>  29
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR2 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  29

Ile Thr Ser Gly Gly Thr Tyr Thr 
1               5               


<210>  30
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvH1 HCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  30

Ala Arg Ser Leu Ala Gly Asn Ala Met Asp Tyr 
1               5                   10      


<210>  31
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR1 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  31

Arg Ala Ser Gln Thr Ile Ser Asp Tyr Leu His 
1               5                   10      


<210>  32
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR2 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  32

Phe Ala Ser Gln Ser Ile Ser 
1               5           


<210>  33
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) (Kabat)

<400>  33

Gln Asn Gly His Gly Phe Pro Arg Thr 
1               5                   


<210>  34
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 (G91A) LCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) 
       (Kabat)

<400>  34

Gln Asn Ala His Gly Phe Pro Arg Thr 
1               5                   


<210>  35
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR1 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  35

Gln Thr Ile Ser Asp Tyr 
1               5       


<210>  36
<211>  3
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR2 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  36

Phe Ala Ser 
1           


<210>  37
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 LCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) (IMGT)

<400>  37

Gln Asn Gly His Gly Phe Pro Arg Thr 
1               5                   


<210>  38
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  hvK3 (G91A) LCDR3 of hB6H12.3 and hB6H12.3 (deamidation mutant) 
       (IMGT)

<400>  38

Gln Asn Ala His Gly Phe Pro Arg Thr 
1               5                   


<210>  39
<211>  488
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Complete Heavy Chain version 1 of a masked anti-CD47 antibody

<400>  39

Gln Gly Ala Ser Thr Ser Val Asp Glu Leu Gln Ala Glu Val Asp Gln 
1               5                   10                  15      


Leu Glu Asp Glu Asn Tyr Ala Leu Lys Thr Lys Val Ala Gln Leu Arg 
            20                  25                  30          


Lys Lys Val Glu Lys Leu Gly Ser Ile Pro Val Ser Leu Arg Ser Gly 
        35                  40                  45              


Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
    50                  55                  60                  


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
65                  70                  75                  80  


Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val 
                85                  90                  95      


Ala Thr Ile Thr Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 
            100                 105                 110         


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
        115                 120                 125             


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Phe Cys 
    130                 135                 140                 


Ala Arg Ser Leu Ala Gly Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr 
145                 150                 155                 160 


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
                165                 170                 175     


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
            180                 185                 190         


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
        195                 200                 205             


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
    210                 215                 220                 


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
225                 230                 235                 240 


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
                245                 250                 255     


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
            260                 265                 270         


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
        275                 280                 285             


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
    290                 295                 300                 


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
305                 310                 315                 320 


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
                325                 330                 335     


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
            340                 345                 350         


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
        355                 360                 365             


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
    370                 375                 380                 


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
385                 390                 395                 400 


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 
                405                 410                 415     


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
            420                 425                 430         


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
        435                 440                 445             


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
    450                 455                 460                 


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
465                 470                 475                 480 


Leu His Asn His Tyr Thr Gln Lys 
                485             


<210>  40
<211>  487
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Complete Heavy Chain version 2 of a masked anti-CD47 antibody

<400>  40

Gln Gly Ala Ser Thr Ser Val Asp Glu Leu Gln Ala Glu Val Asp Gln 
1               5                   10                  15      


Leu Glu Asp Glu Asn Tyr Ala Leu Lys Thr Lys Val Ala Gln Leu Arg 
            20                  25                  30          


Lys Lys Val Glu Lys Leu Gly Ser Ile Pro Val Ser Leu Arg Ser Gly 
        35                  40                  45              


Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 
    50                  55                  60                  


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr 
65                  70                  75                  80  


Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Arg Leu Glu Trp Val 
                85                  90                  95      


Ala Thr Ile Thr Ser Gly Gly Thr Tyr Thr Tyr Tyr Pro Asp Ser Val 
            100                 105                 110         


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
        115                 120                 125             


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ile Tyr Phe Cys 
    130                 135                 140                 


Ala Arg Ser Leu Ala Gly Asn Ala Met Asp Tyr Trp Gly Gln Gly Thr 
145                 150                 155                 160 


Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 
                165                 170                 175     


Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 
            180                 185                 190         


Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 
        195                 200                 205             


Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 
    210                 215                 220                 


Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 
225                 230                 235                 240 


Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 
                245                 250                 255     


Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 
            260                 265                 270         


His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 
        275                 280                 285             


Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 
    290                 295                 300                 


Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 
305                 310                 315                 320 


Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 
                325                 330                 335     


Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 
            340                 345                 350         


Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 
        355                 360                 365             


Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 
    370                 375                 380                 


Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 
385                 390                 395                 400 


Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 
                405                 410                 415     


Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 
            420                 425                 430         


Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 
        435                 440                 445             


Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 
    450                 455                 460                 


Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 
465                 470                 475                 480 


Leu His Asn His Tyr Thr Gln 
                485         


<210>  41
<211>  40
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Heavy Chain masking sequence

<400>  41

Gln Gly Ala Ser Thr Ser Val Asp Glu Leu Gln Ala Glu Val Asp Gln 
1               5                   10                  15      


Leu Glu Asp Glu Asn Tyr Ala Leu Lys Thr Lys Val Ala Gln Leu Arg 
            20                  25                  30          


Lys Lys Val Glu Lys Leu Gly Ser 
        35                  40  


<210>  42
<211>  262
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Complete Light Chain of a masked anti-CD47 antibody

<400>  42

Gln Gly Ala Ser Thr Thr Val Ala Gln Leu Glu Glu Lys Val Lys Thr 
1               5                   10                  15      


Leu Arg Ala Glu Asn Tyr Glu Leu Lys Ser Glu Val Gln Arg Leu Glu 
            20                  25                  30          


Glu Gln Val Ala Gln Leu Gly Ser Ile Pro Val Ser Leu Arg Ser Gly 
        35                  40                  45              


Glu Ile Val Met Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys 
    50                  55                  60                  


Glu Lys Val Thr Leu Thr Cys Arg Ala Ser Gln Thr Ile Ser Asp Tyr 
65                  70                  75                  80  


Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys Leu Leu Ile 
                85                  90                  95      


Lys Phe Ala Ser Gln Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 
            100                 105                 110         


Ser Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala 
        115                 120                 125             


Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Gly His Gly Phe Pro Arg 
    130                 135                 140                 


Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 
145                 150                 155                 160 


Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 
                165                 170                 175     


Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 
            180                 185                 190         


Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 
        195                 200                 205             


Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 
    210                 215                 220                 


Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 
225                 230                 235                 240 


Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 
                245                 250                 255     


Phe Asn Arg Gly Glu Cys 
            260         


<210>  43
<211>  40
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Light Chain masking sequence

<400>  43

Gln Gly Ala Ser Thr Thr Val Ala Gln Leu Glu Glu Lys Val Lys Thr 
1               5                   10                  15      


Leu Arg Ala Glu Asn Tyr Glu Leu Lys Ser Glu Val Gln Arg Leu Glu 
            20                  25                  30          


Glu Gln Val Ala Gln Leu Gly Ser 
        35                  40  


